(lp0
S'1.22 MarketWatch - Oct 31, 2010 ArQule Inc. ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products.'
p1
aS"Important Detailed Discussion about ArQule, Inc.'s  stock price is now ... Hot Stocks Point - 4 hours ago USA based company, ArQule, Inc. 's latest closing price distance was at -18.55% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -11.56% and -3.25% compared with the 20 Day Moving Average."
p2
aS"ArQule, Inc.  Shares Dive as HCC Trial Fails to Meet Primary Endpoint Smarter Analyst - Feb 17, 2017 ArQule, Inc.  shares tumbled nearly 20% this morning after investors learned that the company's METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma  did not meet its primary endpoint of improving overall survival."
p3
aS"ArQule, Inc. 's Liver Cancer Drug Fails: What's Next? Market Exclusive - Feb 20, 2017 ArQule, Inc.  took a real hit at the end of last week, as the company announced data from a late stage oncology trial.ArQule Liver Cancer Drug Fails Phase 3  - InvestopediaTwo Stocks on Trader's Radar: ArQule Inc. , Dean Foods Company ... - The Newburgh Press"
p4
aS'ArQule Is Undervalued Going Into Catalyst Events Seeking Alpha - Oct 21, 2016 ArQule  is a small biopharmaceutical company  engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.'
p5
aS'ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Yahoo Finance - Mar 7, 2017 ArQule, Inc.  today announced its financial results for the fourth quarter and full year of 2016. For the quarter ended December 31, 2016, the Company reported a net loss of $6,820,000 or $0.10 per share, compared with net loss of $2,852,000 or ...'
p6
aS'Annual Global Healthcare Conference on February 15, 2017 Business Wire  - Feb 8, 2017 BURLINGTON, Mass.----ArQule, Inc.  today announced that Paolo Pucci, Chief Executive Officer, and Dr.'
p7
aS'ArQule, Inc.  Upgraded by Zacks Investment Research to Hold Chaffey Breeze - Mar 9, 2017 ArQule, Inc. logo Zacks Investment Research upgraded shares of ArQule, Inc.  from a sell rating to a hold rating in a research note published on Wednesday morning.ArQule, Inc.  Upgraded to Hold at Zacks Investment Research - BBNSAverage Price Target Of 3.08 Issued For ArQule, Inc.  - Fiscal Standard'
p8
aS"Sell-Side Analyst's Predictions: ArQule, Inc. , Array BioPharma Inc.  The USA Commerce - Feb 21, 2017 Shares of ArQule, Inc.  dropped -18.37% to $1.20. During the trading on 02/17/2017, Company's stock ranged from $1.13 to $1.26."
p9
aS'Next Weeks Broker Price Targets For ArQule, Inc.  Fiscal Standard - 14 hours ago Stock market analysts and brokers have recently amended their target prices on shares of ArQule, Inc. . According to the latest research reports released, 0 analysts have issued a rating of buy, 2 analysts outperform, 2 analysts hold, 0 ...Zeroing in on Company Shares of ArQule, Inc.  - Morgan Research'
p10
a.